- •Diabetic Retinopathy
- •Preface
- •Contents
- •Contributors
- •Nonproliferative Diabetic Retinopathy
- •Nonproliferative Diabetic Retinopathy
- •Inflammatory Mechanisms
- •Microaneurysms
- •Vascular Permeability
- •Capillary Closure
- •Classification Of Nonproliferative Retinopathy
- •Macular Edema
- •Risk Factors For Progression Of Retinopathy
- •Severity of Retinopathy
- •Glycemic Control
- •The Diabetes Control and Complications Trial
- •Epidemiology of Diabetes Interventions and Complications Trial
- •The United Kingdom Prospective Diabetes Study
- •Hypertension
- •The United Kingdom Prospective Diabetes Study
- •Appropriate Blood Pressure Control in Diabetes Trials
- •Elevated Serum Lipid Levels
- •Pregnancy and Diabetic Retinopathy
- •Other Systemic Risk Factors
- •Management Of Nonproliferative Diabetic Retinopathy
- •Photocoagulation
- •Scatter Photocoagulation for Nonproliferative Diabetic Retinopathy
- •Scatter Photocoagulation for Proliferative Retinopathy
- •Focal Photocoagulation for Diabetic Macular Edema
- •Other Treatment of Diabetic Macular Edema
- •Medical Therapy
- •Aspirin And Antiplatelet Treatments
- •Aldose Reductase Inhibitors
- •Other Medical Treatments
- •Summary
- •Acknowledgment
- •References
- •Proliferative Diabetic Retinopathy
- •Development and Natural History
- •Histopathology and Early Development
- •Proliferation and Regression of New Vessels
- •Contraction of the Vitreous and Fibrovascular Proliferations
- •Retinal Distortion and Detachment
- •Burned-Out Proliferative Diabetic Retinopathy
- •Systemic Associations
- •Proliferative Diabetic Retinopathy and Glycemic Control
- •Other Risk Factors for Proliferative Diabetic Retinopathy
- •Rubeosis Iridis
- •Anterior Hyaloidal Fibrovascular Proliferation
- •Management of Proliferative Diabetic Retinopathy
- •Pituitary Ablation
- •Photocoagulation
- •Randomized Clinical Trials of Laser Photocoagulation
- •The Diabetic Retinopathy Study
- •Risks and Benefits Photocoagulation In The Drs
- •The Early Treatment Diabetic Retinopathy Study
- •Indications For Photocoagulation of Pdr
- •PRP and Macular Edema
- •PRP Treatment Techniques
- •Vitrectomy for PDR
- •Pharmacologic Treatment of PDR
- •Acknowledgment
- •References
- •Brief Historical Background
- •The Wesdr
- •Prevalence of Diabetic Retinopathy
- •Incidence of Diabetic Retinopathy
- •Diabetic Retinopathy in African American and Hispanic Whites
- •Native Americans and Asian Americans
- •Age and Puberty
- •Genetic and Familial Factors
- •Modifiable Risk Factors
- •Hyperglycemia
- •Clinical Trials of Intensive Treatment of Glycemia
- •Diabetes Control and Complications Trial
- •The United Kingdom Diabetes Prospective Study (UKPDS)
- •Hypertension
- •Lipids
- •Subclinical and Clinical Diabetic Nephropathy
- •Microalbuminuria and Diabetic Retinopathy
- •Gross Proteinuria and Retinopathy
- •Diabetic Retinopathy as a Risk Indicator of Subclinical Nephropathy
- •Other Risk Factors For Retinopathy
- •Smoking and Drinking
- •Body Mass Index and Physical Activity
- •Hormone and Reproductive Exposures in Women
- •Prevalence and Incidence of Visual Impairment
- •Conclusions
- •Acknowledgments
- •References
- •Introduction
- •Fluorescein Angiography
- •Properties
- •Side Effects
- •Normal Fluorescein Angiography
- •Terminology
- •Fluorescein Angiography in the Evaluation of Diabetic Retinopathy
- •Fluorescein Angiography in the Evaluation of Diabetic Macular Edema
- •Optical Coherence Tomography
- •Low-Coherence Interferometry
- •OCT Image Interpretation
- •OCT Technology Development
- •The Role of OCT in Diabetic Macular Edema
- •Morphologic Patterns of Diabetic Macular Edema
- •Clinical Applications of OCT in Diabetic Macular Edema
- •Conclusions
- •References
- •Diabetic primates
- •Type of Diabetes
- •Histopathology and Rate of Development of the Retinopathy
- •Therapies Studied in this Model
- •Advantages and Disadvantages of the Model
- •Diabetic dogs
- •Type of Diabetes
- •Histopathology and Rate of Development of Retinopathy
- •Therapies Studied in this Model
- •Advantages and Disadvantages of the Model
- •Diabetic cats
- •Type of Diabetes
- •Histopathology and Rate of Development of Retinopathy
- •Therapies Studied in this Model
- •Advantages and Disadvantages of the Model
- •Diabetic rats
- •Type of Diabetes
- •Type 1 diabetes
- •Type 2 diabetes
- •Histopathology and Rate of Development of Retinopathy
- •Vascular disease
- •Neuronal disease
- •Therapies or Gene Modifications Studied in this Model
- •Advantages and Disadvantages of the Model
- •Diabetic mice
- •Type of Diabetes
- •Type 1 diabetes
- •Type 2 diabetes
- •Histopathology and Rate of Development of Retinopathy
- •Vascular disease
- •Neural disease
- •Therapies or Gene Modifications Studied in this Model
- •Advantages and Disadvantages of the Model
- •Other Rodents
- •Galactose Feeding
- •Nondiabetic Models in Which Growth Factors are Altered
- •VEGF overexpression
- •IGF overexpression
- •PDGF-B-deficient mice
- •Oxygen-Induced Retinopathy
- •Sympathectomy
- •Retinal Ischemia–Reperfusion
- •Summary
- •References
- •Introduction
- •Biochemistry and Genetics of The Polyol Pathway
- •Aldose Reductase
- •The Aldose Reductase Enzyme
- •The Aldose Reductase Gene
- •Polymorphisms of the AR Gene
- •Sorbitol Dehydrogenase
- •The Sorbitol Dehydrogenase Enzyme
- •The Sorbitol Dehydrogenase Gene
- •Ar Polymorphisms and Risk of Diabetic Retinopathy
- •Sdh Polymorphisms and Diabetic Retinopathy
- •Ar Overexpression
- •Sdh Overexpression
- •Ar “Knockout” Mice
- •Sdh-Deficient Mice
- •Osmotic Stress
- •Oxidative Stress
- •Activation of Protein Kinase C
- •Generation of AGE Precursors
- •Proinflammatory Events and Apoptosis
- •Ari Structures and Properties
- •Effects of Aris in Experimental Diabetic Retinopathy
- •The Polyol Pathway in Human Diabetic Retinopathy
- •The Sorbinil Trial
- •Perspective and Needs
- •Rationale for Defining the Pathogenic Role of the Polyol Pathway
- •Needs to be Met to Arrive at Anti-Polyol Pathway Therapy
- •References
- •Introduction to Diabetic Retinopathy
- •Biochemistry of Age Formation
- •Pathogenic Role of Ages In Diabetic Retinopathy
- •AGEs and Clinical Correlation of Diabetic Retinopathy
- •AGE Accumulation in the Eye
- •Effect of AGEs on Retinal Cells
- •RAGE in Diabetic Retinopathy
- •Other AGE Receptors in Diabetic Retinopathy
- •Anti-Age Strategies For Diabetic Retinopathy
- •Conclusion
- •References
- •Introduction
- •Dag-Pkc Pathway
- •Diabetes and Retinal Blood Flow
- •Basement Membrane and Ecm Changes
- •Vascular Permeability and Angiogenesis
- •Conclusions
- •References
- •Sources of Oxidative Stress in The Diabetic Retina
- •Overview
- •Mitochondrial Electron Transport Chain (ETC)
- •Advanced Glycation End (AGE) Product Formation
- •Cyclo-oxygenase (COX)
- •Flux Through Aldose Reductase (AR) Pathway
- •Activation of Protein Kinase C (PKC)
- •Endothelial NO Synthase (eNOS)
- •Inducible NOS (iNOS)
- •NADPH Oxidase
- •Antioxidants in Diabetic Retinopathy
- •Overview
- •Glutathione (GSH)
- •Superoxide Dismutase (SOD)
- •Catalase
- •Effects of Oxidative Stress in The Diabetic Retina
- •Overview
- •Growth Factors and Cytokines
- •Cytoxicity
- •Therapeutic Strategies For Reducing Oxidative Stress
- •Overview
- •Antioxidants
- •PKC Inhibitors
- •Inhibitors of the Renin-Angiotensin System
- •Inhibitors of the Polyol Pathway
- •HMG-CoA Reductase Inhibitors (Statins)
- •PEDF
- •Cannabinoids
- •Cyclo-oxygenase-2 (COX-2) Inhibitors
- •References
- •Pericyte Loss in the Diabetic Retina
- •Introduction
- •Origin and Differentiation
- •Morphology and Distribution
- •Identification
- •Function
- •Contractility
- •Role in Vessel Formation and Stabilization
- •Loss In Diabetic Retinopathy
- •Rats
- •Mice
- •Chinese Hamster
- •Animal Models Mimicking Retinal Pericyte Loss
- •Pdgf-B-Pdgf-Ssr
- •Angiopoietin-Tie
- •Vegf-Vegfr2
- •Mechanisms of Loss
- •Biochemical Pathways
- •Aldose Reductase
- •Age Formation
- •Modification of Ldl
- •Loss Through Active Elimination
- •Capillary Dropout in Diabetic Retinopathy
- •Diabetic Retinopathy
- •Methods to Measure and Detect Capillary Dropout
- •Models to Study Retinal Capillary Dropout in Diabetes
- •Potential Mechanisms For Capillary Dropout
- •Capillary Cell Apoptosis
- •Proinflammatory Changes/Leukostasis
- •Microthrombosis/Platelet Aggregation
- •Consequences of Capillary Dropout
- •Macular Ischemia
- •Neovascularization
- •Macular Edema
- •Acknowledgments
- •References
- •Neuroglial Dysfunction in Diabetic Retinopathy
- •The Neurons of The Retina
- •The Glial Cells of The Retina
- •Diabetes Reduces Retinal Function
- •Diabetes Induces Neurodegeneration in The Retina
- •Neuroinflammation in Diabetic Retinopathy
- •Historical Perspective on Diabetic Retinopathy
- •Neuroglial Dysfunction in Diabetic Retinopathy.
- •References
- •Introduction
- •Inflammatory Cells Promote and Regulate The Development of Ischemic Ocular Neovascularization
- •VEGF as a Proinflammatory Factor in Diabetic Retinopathy
- •VEGF164/165 as a Proinflammatory Cytokine
- •Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
- •Corticosteroids
- •Anti-VEGF Agents
- •Pegaptanib
- •Ranibizumab and Bevacizumab
- •Conclusions
- •Acknowledgment
- •References
- •Glia-Endothelial Interaction
- •Specialized Retinal Vessels Control Flux into Neural Tissue
- •Overview of Tight Junction Proteins
- •Claudins Confer Tight Junction Barrier Properties
- •Occludin Regulates Barrier Properties
- •Alterations in Occludin in Diabetic Retinopathy
- •Ve-Cadherin and Diabetic Retinopathy
- •Permeability in Diabetic Retinopathy
- •Summary and Conclusions
- •References
- •Introduction
- •Stages of Angiogenesis
- •Vascular Endothelial Growth Factor
- •Regulation of Vegf Expression in The Retina
- •Regulation of VEGF in Proliferative Diabetic Retinopathy
- •Regulation of VEGF in Nonproliferative Diabetic Retinopathy
- •Basic Vegf Biology
- •Receptors
- •Vegf’S Multiple Actions on Retinal Endothelial Cells
- •Main Signaling Pathways
- •Other Actions of Vegf
- •Proinflammatory Effects of VEGF
- •VEGF and Retinal Neuronal Development
- •VEGF and Neuroprotection
- •Modulation of Vegf Action By Other Growth Factors
- •Conclusion
- •References
- •Insulin-Like Growth Factor
- •Basic Fibroblast Growth Factor
- •Angiopoietin
- •Erythropoietin
- •Hepatocyte Growth Factor
- •Tumor Necrosis Factor
- •Extracellular Proteinases
- •The Urokinase Plasminogen Activator System (uPA/uPAR System)
- •Proteinases in Retinal Neovascularization
- •Integrins
- •Endogenous Inhibitors of Neovascularization
- •Pigment Epithelium Derived Growth Factor
- •Angiostatin and Endostatin
- •Thrombospondin-1
- •Tissue Inhibitor of Matrix Metalloproteinases
- •Clinical Implications
- •Acknowledgments
- •References
- •Introduction
- •Pathogenesis
- •Vascular Endothelial Growth Factor (Vegf)
- •Vegf in Physiological and Pathological Angiogenesis
- •Vegf in Ocular Neovascularization
- •Vegf and Diabetic Retinopathy
- •Clinical Application of Anti-VEGF Drugs
- •Pegaptanib
- •Bevacizumab
- •Ranibizumab
- •Use of Anti-VEGF Therapies in Diabetic Retinopathy
- •Safety
- •Clinical Experience with Bevacizumab in Diabetic Retinopathy
- •Ranibizumab in Diabetic Macular Edema
- •Effect on Foveal Thickness and Macular Volume
- •Effect on Visual Acuity
- •Summary
- •References
- •Introduction
- •Pkc Inhibition With Ruboxistaurin
- •Early Clinical Trials With Rbx
- •Rbx and Progression of Diabetic Retinopathy
- •Ongoing Trials With Rbx
- •Rbx and Other, Nonocular Complications of Diabetes
- •Safety Profile of Rbx
- •Clinical Status of Rbx
- •Conclusions
- •References
- •The Role of Intravitreal Steroids in the Management of Diabetic Retinopathy
- •Clinical Efficacy
- •Safety
- •Pharmacology
- •Pharmacokinetics
- •Combination With Laser Treatment
- •Clinical Guidelines
- •Macular Edema Caused by Focal Parafoveal Leak
- •Widespread Heavy Diffuse Leak
- •Macular Edema and High-Risk Proliferative Retinopathy
- •Macular Edema Prior to Cataract Surgery
- •Juxtafoveal Hard Exudate With Heavy Leak
- •Control of Systemic Risk Factors
- •The Future of Intravitreal Steroid Therapy
- •References
- •Overview
- •Introduction and Historical Perspective
- •Growth Hormone and Diabetic Retinopathy
- •The IGF-1 System and Retinopathy
- •The Role of SST in Diabetic Retinopathy
- •Rationale for the Clinical use of Octreotide
- •Clinical evidence for sst as a therapeutic for pdr
- •Potential Reasons for Mixed Success in Clinical Trials
- •Future Direction: Sst Analogs in Combination Therapy
- •Conclusion
- •Acknowledgements
- •Introduction
- •Diabetic Retinopathy and Mortality
- •Diabetic Retinopathy and Cerebrovascular Disease
- •Diabetic Retinopathy and Heart Disease
- •Diabetic Retinopathy, Nephropathy, and Neuropathy
- •Conclusion
- •References
- •Name Index
256 |
Pfister et al. |
MECHANISMS OF LOSS
The underlying causes and mechanisms of early pericyte dropout in diabetic retinopathy remain still unclear. It is possible that pericyte loss is a result of passive processes, such as degeneration and apoptosis. For example, STZ-diabetic Wistar rats showed a 2.65 fold increase in the numbers of TUNEL positive cells (including pericytes) in retinae after 11 months of hyperglycemia (105). Pericyte death was also present in retinal vessels of diabetic patients suggesting its relevance in clinical disease (106).
Biochemical Pathways
ALDOSE REDUCTASE
The selective damage of pericytes by chronic hyperglycemia may be explained by altered biochemical pathways which have been implicated in the pathogenesis of microvascular damage, so that pericyte loss may be the consequence of hyperglycemic toxicity. The four biochemical pathways that have been discussed over years to be involved in the pathogenesis of diabetic complications are i. increased activity of the polyolpathway, ii. activation of PKC isoforms by de novo synthesis of diacylglycerol, iii. increased flux through the hexosamine pathway and iiii. supply of glycolytic intermediates for the formation of AGEs. The first pathway to be studied in this regard was the aldose reductase pathway, as immunological evidence had suggested the selective presence of aldose reductase in pericytes (107). When glucose levels in cells are low, the enzyme aldose reductase functions by detoxifying aldehydes to inactive alcohols. When glucose levels in cells rise in diabetes, the enzyme starts to reduce glucose to sorbitol, and this process consumes the cofactor NADPH. Since NADPH is an essential cofactor for the regeneration of an important intracellular antioxidant, reduced glutathione, its depletion may induce a significant impact on cellular defense against oxidative stress. According to novel findings, the expression and the activity of aldose reductase are increased in bovine retinal pericytes in vitro when cultured in high glucose (108), and are accompanied by elevated intracellular sorbitol levels. Whether this leads to increased pericyte death and is amenable to pharmacological inhibition has not yet been demonstrated. Overall, in line with the notion that the absolute levels of aldose reductase in the retina may be too low to contribute significantly to retinopathy development, the majority of experimental, and one large clinical trial failed to establish this pathway as playing a major role.
AGE FORMATION
Chronic hyperglycemia-induced formation of reactive oxygen species and AGEs, which accumulate in pericytes in vivo (109), might be able to initiate pericyte degeneration. Injection of exogenous AGE into nondiabetic animals resulted in a selective uptake in pericytes (110). In principle, repeated injection of high doses of AGE-modified rat serum can induce selective pericyte loss in normal rats after 2 weeks (111). Moreover, endogenous AGEs can form and accumulate in pericytes (112). While the ingestions of exogenous AGEs is consistent with the propensity of phagocytosis of pericytes, the formation of endogenous AGEs in pericytes is inconsistent with the prior finding that
